Aclarion Inc., a Broomfield-based health care technology firm, has announced the extension of its commercial agreement with the prestigious London Clinic. This contract expansion signifies increased payment for each Nociscan use, efforts to secure payer coverage decisions from top private health insurers, and strategies to enhance access to Nociscan within the greater London market.
Aclarion, utilizing biomarkers and proprietary augmented intelligence algorithms, helps physicians pinpoint the source of chronic low back pain. The company’s product, Nociscan, adds a unique dimension in diagnosing chronic low back pain that traditional anatomical imaging can’t provide by quantifying the chemical biomarkers present in lumbar intervertebral discs, said Dr. Simon Blease, consultant musculoskeletal radiologist at The London Clinic. He added the product had showcased “compelling results” in over 20 patients and is set to transform how treatment for the condition is evaluated and planned.
Initially, Aclarion’s agreement with The London Clinic intended to assess the clinical value of Nociscan. However, after witnessing considerable benefits in a relatively small sample size of patients, the physicians supported a contract extension. This move aims at enhancing access to Nociscan for patients via extending outreach to referring doctors, escalating the compensation to Aclarion, and engaging payer communities to establish private insurance coverage for Nociscan.
“London represents the advanced nature of healthcare,” said Brent Ness, CEO at Aclarion, noting that extending their relationship with The London Clinic made London a significant hub for Nociscan. Ness also highlighted how The London Clinic took the initiative to extend the contract, advocating for coverage and expanding access to referring physicians, a strategy similar to the one pursued with key opinion leaders across the U.S.
Chronic low back pain persists as a global health concern with approximately 266 million people globally suffering from degenerative spine disease and low back pain. Up to a third of the UK adult population is affected by low back pain yearly.
Source: Press Release